Menactra Vaccine Immunogenicity

Helps protect against 4 vaccine–preventable serogroups1,2

Five serogroups, A, B, C, Y and W-135 are responsible for almost all cases of invasive meningococcal disease worldwide.3

  • Menactra is the first meningococcal conjugate vaccine in the United States that helps protect against 4 vaccine-preventable serogroups (A, C, Y, and W-135).1,2,4

Immunogenicity proven in clinical trials — confirmed in everyday use1

Large comparative trials were conducted in children 2 through 10 years of age, adolescents 11 through 18 years of age, and adults through 55 years of age to compare the immune responses elicited by Menactra and Menomune®-A/C/Y/W-135 (Meningococcal Polysaccharide Vaccine, Groups A, C, Y and W-135 Combined) vaccines.1,6

The immune responses to Menactra and Menomune-A/C/Y/W-135 vaccines were comparable for all 4 serogroups1,6.

Multicenter studies demonstrated1:

  • 86% to 100% of infants achieved protective levelsa at 1 year of age after 2 doses given 3 months apart
  • Adolescents achieved robust immune responses after 1 dose

a Protective levels = serum bactericidal assay — human complement titers ≥1:8.

Important Safety Information

Indication

Menactra vaccine is indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135. Menactra vaccine is approved for use in individuals 9 months through 55 years of age. Menactra vaccine does not prevent N meningitidis serogroup B disease.

Safety Information

The most common local and systemic adverse reactions to Menactra vaccine include pain, redness, and swelling at the injection site and appetite loss (all age groups); induration at the injection site and diarrhea (all age groups except infants); irritability and drowsiness (infants and children); abnormal crying, vomiting, and fever (infants); headache, fatigue, malaise, and arthralgia (adolescents and adults). Other adverse reactions may occur.

Menactra vaccine is contraindicated in persons with a known hypersensitivity (eg, anaphylaxis) to any component of the vaccine. Persons previously diagnosed with Guillain-Barré syndrome (GBS) may be at increased risk of GBS following receipt of Menactra vaccine. GBS has been reported in temporal relationship following administration of Menactra vaccine. The decision to give Menactra vaccine should be based on careful consideration of the potential benefits and risks. Syncope (fainting) can occur in association with administration of injectable vaccines, including Menactra vaccine. Procedures should be in place to prevent falling injury and manage syncopal reactions. Vaccination with Menactra vaccine may not protect all individuals.

Before administering Menactra vaccine, please see accompanying full Prescribing Information.

PLEASE NOTE

By clicking on this link, you will be leaving this Sanofi Pasteur website and going to another Sanofi Pasteur website.

This link has opened in a new window. To return to your original site, please close this new window.

Click here to go to the page you requested. Close window and return to site.

PLEASE NOTE

By clicking on this link, you will be leaving this Sanofi Pasteur website, and going to another, entirely independent, website. Sanofi Pasteur provides this link as a service to its website visitors; however, it takes no responsibility for the information presented on any website but its own.

This link has opened in a new window. To return to your original site, please close this new window.

Click here to go to the page you requested. Close window and return to site.